Background. To evaluate the in vivo safety, biodistribution, and diagnostic accuracy of a monoclonal Fab' antibody (S12) that is specific for the platelet membrane glycoprotein (GMP-140) expressed during platelet activation at vascular injury sites, 11 peripheral percutaneous transluminal angioplasty (PTA) patients (age, 61±8 years) with severe vascular disease had serial mTc S12 radionuclide imaging at 5 and 90 minutes, 4-6 hours, and 20-24 hours after a total of 23 angiographically successful PTA procedures. No acute allergic reactions or hematologic toxicity occurred.
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Methods
Patient Population
The patient population was drawn from the University of Texas Health Science Center teaching hospitals (Medical Center Hospital, Audie L. Murphy Veterans Administration Hospital) in San Antonio. Eleven patients aged 61±8 years (10 men and one woman) with severe peripheral vascular disease producing rest pain (n = 8) and/or tissue loss (n = 8) gave informed consent to participate in this study. All patients were evaluated by an experienced interventional radiologist (J.C.P. or F.J.R.) before angioplasty. The distribution of 23 angioplasty sites was iliac (n=2), superficial femoral (n=6), profunda femoral (n=1), popliteal (n=5), and tibialperoneal (n=9) arteries.
Angiography
All diagnostic studies and angioplasty procedures were performed using a digital subtraction angiography system (General Electric LUA or Phillips DVI) with a 9-in. field image intensifier and 512x512 image matrix. Unzoomed images were formatted with grading of masked and unmasked x-rays.
Intra-arterial nitroglycerin (400 ,jg) was given to ensure maximal vasodilatation before angiography. All patients received heparin (5,000 U intra-arterially) during angioplasty and by continuous infusion for hours after the angioplasty procedure. Coumadin (n =3) and urokinase (n=2) were coadministered in selected patients for clinical reasons. Three patients had received aspirin within 1 week of the PTA procedure.
Angiographic percent luminal diameter stenosis (DS) severity was graded before and after the procedure at each angioplasty site by two experienced radiologists blinded to the experimental protocol. The mean pre-PTA to post-PTA percent change in stenosis severity was calculated (percent delta stenosis). Procedurally complicated PTA was prospectively defined as either dilation of an extensive (>2 cm) arterial segment or grade I or greater intimal dissection. This occurred at 10 PTA sites. Angiographic PTA success, present in all studies, was prospectively defined as a >30% decrease in the pre-PTA luminal percent DS to a residual postangioplasty luminal percent DS of 50% or less.
Side Effects and Safety Monitoring
Patients with previous exposure to monoclonal antibodies or mouse protein (i.e., animal laboratory technicians) were prospectively excluded from these studies. All patients underwent a detailed history and physical examination, including evaluation of vital signs and baseline hematologic and biochemical blood analysis.
For 1 hour after injection, each patient underwent serial monitoring of vital signs and repeated questioning for symptoms of local or systemic allergic reaction. A postinjection physical examination and evaluation of hematologic and biochemical parameters were performed at 24 hours. All patients remained hospitalized for at least 5 days after antibody injection and under99niTc Monoclonal Antibody Preparation
The Fab' fragment was prepared from hybridomaproduced IgG by pepsin digestion followed by reduction of the F[ab'j2 with dithiothereitol. The purified S12 Fab'antibody fragment was labeled with i9mTc using the two-vial "kit" method of Pak et al. 21 One milliliter of TC04 (20-40 mCi/ml) was eluted from a 99mTct9OMo generator and transferred into a lyophilized vial containing 12.5 mg D-glucarate and 150 mg stannous chloride. After incubation at room temperature for 2 minutes, 400 ,ul 99mTc was mixed with 400 ,ul Fab'.
The final specific activity was 20 mCi/mg and the protein concentration was 1 mg/ml in the labeling solution. The incorporation of 99mTc was quantitated by gel filtration-high-performance liquid chromatography equipped with radiometric detector and instant thinlayer chromatography (ITLC, Gelman Sciences). Preparations with labeling efficiency of >90% were used. 99mTc S12 Radionuclide Imaging Protocol 99"Tc S12 Fab' monoclonal antibody (15 mCi) was injected via an upper extremity vein followed by a 10-ml saline flush. All doses were evaluated by a radiation calibration system before administration. Imaging of the injection site confirmed no infiltrated doses. A 99mTc marker was used to locate the level of the knee before image acquisition (10 seconds) and was then removed. Efforts were made to minimize patient motion. All patients were well hydrated and encouraged to void before and after imaging. In selected patients, an ovalshaped lead shield was used to attenuate secondary activity in the bladder and/or gonads. 99mTc S12 Fab' injection was performed within 24 hours after angioplasty. Radionuclide imaging was performed with a large field-of-view planar gamma camera (Scintronix Co.) equipped with a high-resolution collimator. Images were acquired without the use of a zoom function into a 128x 128-byte computer matrix.
Image acquisition time was 2, 5, 10, and 10 minutes per view at 5 minutes, 90 minutes, 4-6 hours, and 20-24 hours after injection, respectively. Anterior and posterior images of the pelvis and leg above and below the knee were obtained. All images were acquired by a nuclear medicine technologist with previous experience using 99'Tc S12 in an animal angioplasty model. ' 
Results
Qualitative Image Analysis
As summarized in Figure 1 , the biodistribution of 99mTc S12 5 minutes after injection demonstrated significant blood pool activity that gradually decreased by 90 minutes. Local 9'Tc S12 activity visualization at angioplasty sites was optimal at 4-6 hours after injection. Regional accumulation of 9'9Tc S12 antibody activity, distinct from blood pool and background, was qualitatively evident in 18 of 23 (78%) angioplasty sites. Two iliac angioplasty sites (one common and one external) were not well visualized because of significant adjacent bladder activity despite the use of a catheter to enhance renovesicular activity excretion in one patient. In addition to this, one popliteal, one tibial-peroneal, and one common femoral site did not demonstrate increased local 'Tc S12 activity despite low background counts.
Residual activity was still noted in nine of 23 angioplasty sites (39%) at 20-24 hours after injection. Activity distinct from blood pool was noted at arteriotomy puncture sites (femoral, six; brachial, one) in seven of 11 patients.
Secondary activity was greatest in the kidney and bladder, the sites of antibody excretion blood pool clearance. Additional variable secondary activity was noted in the spleen and liver up to 4-6 hours after injection. Vertebral and iliac bone marrow activity was observed in five of 11 patients beyond 90 minutes after injection. Minimal background activity was noted in soft tissue and muscle adjacent to arterial PTA segvascular 99mTc S12 visualization in the majority (91%) of arterial injury sites.
Quantitative Image Analysis
Regional antibody clearance kinetics. In addition to initial 99'Tc S12 antibody binding to GMP-140 platelet sites, the early (<6 hours) and late (6-24 hours) clearance rates of 99mTc S12 activity may also contribute to regional vascular differences in activity after radiotracer injection.
The overall 0-24-hour postinjection clearance halftime for 99mTc S12 activity in angioplasty sites, contralateral arteries, and background muscle averaged 208+9, 205 + 10, and 220±21 minutes, respectively (p=NS). The early (5 minutes to 4-6 hours) clearance half-time for 99mTc S12 activity averaged 57±9, 56+10, and 67+22 minutes in the same ROIs (p=NS). The most significant change in regional activity occurred between the 5-and 90-minute image sets, with 72±5%, 75+6%, and 68±13% of initial activity clearing over this time interval in these ROIs. The percent of original (5 minutes after injection) activity that had cleared by 4-6 hours after injection was 94±3%, 94±2%, and 90+7% in PTA sites, contralateral arteries, and background muscle, respectively (Figures 2A and 2B ). Overall clearance rates did not differ significantly between complicated and uncomplicated angioplasty sites (209± 6 versus 199+12 minutes; p=NS; Figure 2C ). 99mTc S12 activity in angioplasty sites. Angiographic data in procedurally complicated and uncomplicated sites are summarized in Figure 3 (also see Table 1 ). Two patients had extensive >2-cm dilatation, and four patients experienced intimal dissection. The mean 'mTc S12 activity ratio was higher in 18 qualitatively visualized angioplasty sites at or below the level of the inguinal ligament (1.7+0.5 versus 1.1±0.1; p<0.05). The 4-6-hour postinjection 99'Tc S12 activity ratio averaged 1.6±0.5 for all 23 sites, ranging from 1.0 in an uncomplicated external iliac artery site (adjacent to bladder activity) to 2.9 in an extensive popliteal-tibialperoneal artery angioplasty site that required multiple prolonged inflations (see Figure 4) . Nine angioplasty sites (four complicated and five uncomplicated) with persistently visible 20-24-hour postinjection 99mTc S12 activity had a mean 99mTc S12 activity ratio of 1.5±0.4 (see Figure 5) , including a value of 2.0 at one superficial femoral site with grade I dissection and at another complex angioplasty of a 6-cm popliteal artery-vein graft anastomosis.
The 4-6-hour 9'Tc S12 activity ratios in 10 procedurally complicated and 13 uncomplicated sites were 1.9+0.5 and 1.2±0.1, respectively (p<0.01; see Figure  6 ). The 4-6-hour target-to-background (muscle) ratio was 2.3 ±0.6 and 4.4+1.7 at all 23 angioplasty and seven visible arteriotomy sites, respectively.
There was no significant linear or nonlinear correlation between the pre-or post-PTA percent DS and the quantitative 4-6-hour "'Tc S12 activity ratio when all PTA sites were analyzed. and supported a successful angiographic result (see Figure 7 ). These patients did not differ clinically from the other patients; both received heparin during and after the angioplasty procedure. The extensive balloon dilation of arterial segments (four serial lesions over 16 cm in one and one continuous site of 6 cm in the other) may have contributed to rheological disturbances predisposing platelet activation despite angiographic PTA success in these patients.
Coumadin and urokinase were administered to three patients (one received coumadin only, and two received coumadin and urokinase). The mean 4-6-hour S12 injury ratio in these patients (five sites) was 1.4±0.3. Of interest, all three patients exhibited 24-hour S12 activity in at least one angioplasty site (mean activity ratio, 1.5±0.5). The 99mTc S12 activity ratio in this subset of three patients (five PTA sites) receiving coumadin/ urokinase was not significantly different from that observed in the other patients.
Initially, distal perfusion was improved by angioplasty in association with restoration of pulses, improved skin temperature, and angiographic runoff in all patients. Four patients with advanced distal vascular disease subsequently proceeded to limited amputation because of tissue loss or revascularization associated with recurrent severe rest pain at 13±6 days after angioplasty. Two patients required subsequent distal arterial embolectomy. The 4-6-hour and 24-hour 99mTc S12 activity ratios were not correlated with the occurrence of these complications.
Acute Toxicity Evaluation
Monitoring of vital signs before and during the first hour after injection demonstrated no significant change 33 .5±9.7 seconds before injection and 35.9±13.5 seconds after injection (p=NS). Bleeding time was 3.6±1.8 minutes before injection and 4.3±2.7 minutes after injection (p=NS). There was no significant change in the quantitative platelet count from the pre-to postinjection (24-72-hour) time points (397±131 to 408±154x 103/mm3; p=NS).
Discussion
The current clinical study confirms previous "'Inlabeled platelet imaging studies23-26 and extends our experimental observations'722 by demonstrating significantly increased local 99mTc-labeled monoclonal S12 Fab' antibody activity at sites of angioplastyinduced vascular injury in human atherosclerotic arteries. The presumed mechanism of this increase is S12 antibody binding to the translocated a-granule membrane glycoprotein (GMP-140) expressed at the surface of activated platelets in vascular balloon injury sites. '5'16 Significant '9mTc S12 activity was observed despite angiographic patency and in the absence of visible thrombus, particularly in complex angioplasty sites and at sites with a suboptimal pre-to postangioplasty percent diameter stenosis reduction. Residual postangioplasty turbulence and increased shear stress associated with a suboptimal procedural result are known to contribute to local platelet activation.23,2427 Arterial damage and resulting changes in vascular shear rate can affect platelet activation in patients.28.29 Significantly increased thrombus formation occurs in association with increasing shear stress in deep arterial injury models30 and an ex vivo swine arterial model. 31 Two patients who required extensive areas of dilation with a satisfactory angiographic result and no evidence of dissection demonstrated markedly increased local 99mTc S12 activity at five angioplasty sites. Increased local vascular 99mTc S12 binding at these sites may have been predisposed by individual biological and/or local rheological factors.
The comparability of 'mTc S12 activity clearance kinetics between the angioplastied and unoperated contralateral vascular ROIs implies that the greatest con- [20] [21] [22] [23] [24] hours after injection (1.5+±0.4). Continued 99mTc S12 activity implies sustained S12-GMP-140 binding at angioplasty site.
tribution to the initial decrease in local 99mTc S12 activity was clearance of blood pool counts between 5 minutes and 4-6 hours after injection (see Figure 2) . The qualitative and quantitative contrast between angioplasty site versus contralateral artery ttmTc S12 activity became apparent at 4-6 hours after injection after clearance of blood pool 99mTc S12 activity.
The absence of significant toxicity, the potential for wide availability of a 'tmTc "kit" method for labeling S12, and the adaptability of this technique to current gamma camera imaging technology make this an attractive noninvasive method for identifying local in vivo platelet activation at vascular injury sites. Further studies will determine the applicability of this technique to coronary and abdominal (i.e., renal) angioplasty sites and the clinical value of noninvasive ttmTc S12 vascular imaging for the detection of thrombotic complications or PDGF-mediated events leading to subsequent vascular reocclusion. Safety Evaluation Other than the need for intravenous injection, the gamma camera imaging technique used is totally noninvasive, with radiation exposure similar to other routine diagnostic scans. Dosimetry studies in the rabbit, supported by biodistribution data in the current clinical study, indicate that the kidney is the critical organ (0.0885 mGy/MBq; 0.327 radian/mCi). The sustained 20-24-hour activity observed in the kidneys and bladder reflects the fact that the urine is the primary route of Fab' antibody excretion. Frequent voiding or the placement of a urethral catheter should decrease the radiation burden to the bladder.
As with the administration of any murine monoclonal antibody, a risk of allergic reaction exists. However, the potential for such reaction is reduced by the use of small Fab' fragments for imaging. Extensive toxicity studies, including rechallenge of rabbits with second doses of antibody, have failed to demonstrate any hypersensitivity reactions (Centocor, data on file). No local urticarial or hypersensitivity reactions occurred after 99`Tc S12 injection, and patients did not complain of local injection site discomfort. Vital signs (see Table 2 ) were unchanged from preinjection levels during 1 hour of monitoring after injection.
Detailed analysis of blood biochemistry and hematologic data indicated no significant derangements from preinjection levels. In particular, platelet inhibitory, 
Clinical Implications
The release of PDGF from the platelet a-granule is postulated to predispose to smooth muscle cell hyperproliferative restenosis.4-7 New technical and pharmacological approaches designed to take advantage of the growing basic understanding of the role of local growth factor secretion in the biology of vascular injury and the pathogenesis of postangioplasty restenosis have been difficult to evaluate because a simple noninvasive in vivo measure of local platelet activation has been lacking. 27 The current study demonstrates for the first time in humans that a platelet membrane-targeted, specific monoclonal antibody, when radiolabeled for noninvasive imaging, can safely identify the majority (78%) of recent angioplasty injury sites in 91% of patients studied (10 of 11) without significant image degradation or loss of specificity caused by blood pool activity. The observed association of higher local 9'9Tc S12 activity at angiographically patent but procedurally complicated angioplasty sites correlates with previous basic studies of quantitative platelet deposition at sites of increased vascular turbulence23,24 and abnormal rheology.30 '3' The mechanisms and rates of postangioplasty restenosis in the peripheral32 and coronary beds'-4.8,9,33 are comparable. Our initial clinical experience with "mTc S12 imaging of a coronary angioplasty patient,34 as well as nonimaging flow cytometric data confirming augmented platelet GMP-140 expression in the coronary effluent of angioplasty patients19 and unstable angina patients,28 supports the possible extension of these peripheral vascular studies to the setting of coronary angioplasty and acute ischemic coronary syndromes. The widely postulated and experimentally supported hypothesis4-7.27.29 that local thrombosis and growth factor release are important mediators of hyperproliferative restenosis may now be evaluable in humans by using longitudinal angiographic and S12 scintigraphic studies. 
